Why AstraZeneca's Potential Vaccine Is More Exciting Than You Think
In the last three weeks, the world has let out a collective sigh of relief on positive news from coronavirus vaccine trials reported by Pfizer (NYSE: PFE) and partner BioNTech (NASDAQ: BNTX), Moderna (NASDAQ: MRNA), and AstraZeneca (NASDAQ: AZN). But while the market cheered more than 90% efficacy of the first two vaccine candidates, the results from AstraZeneca's clinical trials were met with more of a shrug. Despite the market's reaction, I think investors have more to be excited about from the potential AstraZeneca vaccine than its efficacy data suggests.
With so many vaccines under development -- the New York Times' Coronavirus Vaccine Tracker lists 74 in clinical trials or approved for limited use -- it can be difficult to understand what might make any one vaccine better than the others. One clear way is knowing how effective they are at preventing the disease. But as it turns out, even that can be a little misleading.
Image source: Getty Images.
Source Fool.com
